No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Ap26113 is a drug used in the treatment of non-small cell lung cancer (NSCLC). It is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is a key component of the EGFR signaling pathway. Ap26113 works by blocking the activity of the EGFR, which is involved in the growth and spread of cancer cells. This drug is used in combination with other chemotherapy drugs to treat NSCLC.
Ap26113 is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is currently being studied in clinical trials for its potential to treat other types of cancer, such as colorectal and pancreatic cancer.
The Ap26113 market is a rapidly growing one, with a number of companies developing and marketing the drug. These include AstraZeneca, Merck, Pfizer, and Novartis. Other companies, such as Boehringer Ingelheim and Eli Lilly, are also involved in the development and marketing of Ap26113. Show Less Read more
